You, or a loved one, are facing one of the greatest battles of your life. There was nothing that you did to cause a diagnosis of leukemia, but you sure are going to do everything that you can do fight the disease. For you, or your loved one, that may mean participating in clinical trials of new drugs to fight your cancer such as the one run by Ariad Pharmaceuticals for its leukemia drug Iclusig. However, the clinical trial has abruptly ended and it is important for you to know why.
FDA and Ariad Pharmaceuticals Identify Potentially Serious Iclusig Dangers
In October 2013, Ariad Pharmaceuticals’ Iclusig trials were suddenly stopped. The information provided by the FDA and the drug manufacturer indicate that:
- 48% of patients who took Iclusig during an early-stage clinical trial suffered serious side effects.
- 24% of patients who took Iclusig during a mid-stage clinical trial suffered serious side effects.
- Those serious side effects reportedly included blood clots, heart attacks, strokes, and death.
- The FDA cannot identify a safe dosage or a safe amount of time for patients to take Iclusig. According to the FDA, some patients suffered side effects from Iclusig in as little as two weeks after beginning the drug.
While the marketing of Iclusig is currently on hold in the United States, Ariad has reportedly indicated that it would like to resume sales of Iclusig in the future.
Call a Kentucky Pharmaceutical Injury Lawyer if You’ve Been Hurt or if You’ve Lost a Loved One
The Iclusig dangers may have caused some patients significant harm or even death. If you think that you, or a loved one, may have suffered as a result of this leukemia drug then we encourage you to find out more about your legal rights and your potential legal recovery.
Our experienced Kentucky pharmaceutical injury attorneys would be pleased to provide you with a FREE initial consultation so that you can make the legal decisions that are in the best interest of you and your family. Please call us today at 800.634.8767 or 502.210.8942 for more information.